Independent validation of the PAM50-based chemo-endocrine score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-targeted therapy
- Citation:
- Ann Oncol vol 31 (Supplement 2) S17
- Meeting Instance:
- ESMO Breast 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Following different anti-HER2 combinations in HR+/HER2+ BC across 8 studies: CHERLOB, OptiHER, LPT109096, ICO, HCB, Per-ELISA and C40601.
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3680